Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0DADTW |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-B7H3 |
|||||
| Organization | DUALITY BIOLOGICS (SUZHOU) CO., LTD. |
|||||
| Synonyms |
Anti-B7H3
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antigen Name | CD276 antigen (CD276) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
WBP301088-X2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
4.8 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1568 cells | CVCL_1476 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
11.4 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
52.3 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Lung adenocarcinoma | Calu-6 cells | CVCL_0236 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
55.5 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
86.5 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Glioblastoma | U87 MG cells | CVCL_0022 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
164.7 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Amelanotic melanoma | A375 cells | CVCL_0132 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
180.8 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Prostate carcinoma | PC-3 cells | CVCL_0035 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
268.8 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Breast carcinoma | CAL-120 cells | CVCL_1104 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
369.3 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Lung adenocarcinoma | A549 cells | CVCL_0023 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
446 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Colon adenocarcinoma | HT-29 cells | CVCL_0320 | ||